Welcome to our dedicated page for Kala Pharmaceuticals news (Ticker: KALA), a resource for investors and traders seeking the latest updates and insights on Kala Pharmaceuticals stock.
Kala Pharmaceuticals Inc (NASDAQ: KALA) is a clinical-stage biopharmaceutical company pioneering novel therapies for severe ocular diseases through its proprietary MSC-S platform and nanoparticle drug formulations. This page provides authorized updates on KALA's clinical developments, regulatory milestones, and research advancements.
Investors and researchers will find verified press releases covering Phase 2/3 trial progress for lead candidate KPI-012 in PCED treatment, FDA designations for rare disease therapies, and peer-reviewed study publications. All content is curated to meet strict journalistic standards for accuracy in biopharmaceutical reporting.
The news archive includes updates on corneal healing therapies, retinal disorder research collaborations, intellectual property developments, and scientific conference presentations. Content is organized chronologically with clear sourcing to enable efficient tracking of the company's progress in ocular regenerative medicine.
Bookmark this page for direct access to Kala Pharmaceuticals' official announcements, including trial enrollment updates, partnership disclosures with academic institutions, and manufacturing scale-up progress. Check regularly for the latest validated information on this innovative developer of first-in-class ocular biologics.
Kala Pharmaceuticals (NASDAQ:KALA) announced on December 17, 2021, the grant of non-statutory stock options to four new employees, totaling 13,500 shares. The options were issued as inducement awards outside the 2017 Equity Incentive Plan and have an exercise price of $1.44 per share, reflecting the stock's closing price on the grant date. Options will vest over four years, with 25% vesting after the first year and the rest in monthly installments, contingent on continued employment.
Kala Pharmaceuticals announced the granting of non-statutory stock options to new employees as inducement awards under Nasdaq Listing Rule 5635(c)(4). A total of 131,500 shares were granted to three new employees following the acquisition of Combangio, including 100,000 shares to Darius Kharabi, the new Chief Business Officer. The options have an exercise price of $2.10 per share and a ten-year term, with vesting over four years. These steps align with the company’s ongoing focus on innovative therapies for eye diseases.
Kala Pharmaceuticals reported $3.1 million in net revenue for Q3 2021, up from a year earlier, with EYSUVIS prescriptions rising by 19% compared to Q2 2021. The company has expanded its pipeline through the acquisition of Combangio, focusing on KPI-012, for treating rare ocular surface diseases. However, the net loss for Q3 2021 was $28.1 million or $0.43 per share, slightly higher than the $27.9 million loss in Q3 2020. The financial outlook expects operational funding through Q2 2023, considering ongoing revenue generation and cost containment strategies.
Kala Pharmaceuticals has acquired Combangio, a clinical-stage company, to enhance its pipeline for severe ocular surface diseases. The acquisition includes KPI-012, a promising therapy for persistent corneal epithelial defect (PCED). The Phase 1b trial showed positive results, with six out of eight patients achieving complete healing. Kala plans to submit an IND application to the FDA and initiate a Phase 2/3 trial in 3Q 2022. Mark S. Blumenkranz joins Kala's Board of Directors as part of this strategic move, expected to strengthen its offerings in eye health.
Kala Pharmaceuticals (NASDAQ:KALA) has rescheduled its financial results conference call to report Q3 2021 results on November 15 at 10:30 AM ET. The call will provide a business update, with access available via dial-in or a live webcast on the company's investor site. Kala focuses on innovative therapies for eye diseases, featuring products like EYSUVIS and INVELTYS, utilizing the AMPPLIFY Drug Delivery Technology. For further details, visit their website.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has announced its participation in two upcoming virtual healthcare investor conferences in November 2021. The Jefferies London Healthcare Conference will feature a pre-recorded fireside chat available on November 18, 2021, starting at 3:00 am ET. Additionally, management will engage in a virtual fireside chat at Ophthalmology Day at BTIG on November 30, 2021, at 10:00 am ET. Kala is known for its innovative therapies for eye diseases, including EYSUVIS® and INVELTYS®. For more details, visit kalarx.com.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) will report its third quarter 2021 financial results on November 15, 2021. A conference call is scheduled for 8:30 a.m. ET to discuss these results and provide a business update. The company focuses on developing innovative therapies for eye diseases using its AMPPLIFY® mucus-penetrating particle Drug Delivery Technology. Its key products include EYSUVIS® for dry eye disease and INVELTYS® for post-operative inflammation following ocular surgery. Further details and the live webcast are available on Kala's website.
Kala Pharmaceuticals (NASDAQ: KALA) announced the grant of non-statutory stock options to ten new employees as inducement awards apart from its 2017 Equity Incentive Plan, complying with NASDAQ Listing Rule 5635(c)(4). The options, totaling 70,000 shares, were granted on October 18, 2021, with an exercise price of $1.85 per share. The options have a ten-year term and vest over four years, with 25% vesting after the first year. This move aims to attract and retain talent while aligning employee incentives with shareholder interests.
Kala Pharmaceuticals (NASDAQ: KALA) has appointed C. Daniel Myers to its Board of Directors as a Class III director. With over 35 years in ophthalmic pharmaceuticals, Myers will contribute to the Compensation and Nominating Committees. CEO Mark Iwicki expressed optimism about Myers' extensive background, emphasizing its potential to enhance Kala's commercial strategies, particularly for its products EYSUVIS and INVELTYS. Concurrently, Rajeev Shah will step down from the Board after significant contributions since 2015, marking a leadership transition for the company.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) announced the granting of non-statutory stock options to eleven new employees, totaling 112,000 shares, as inducement awards compliant with NASDAQ Listing Rule 5635(c)(4). The options granted on September 15, 2021, have an exercise price of $3.08 per share, matching the closing price on that date. The awards vest over four years, with 25% vested after the first year and the remainder vesting monthly. The initiative aims to attract talent in the biopharmaceutical sector focused on innovative ocular therapies.
FAQ
What is the current stock price of Kala Pharmaceuticals (KALA)?
What is the market cap of Kala Pharmaceuticals (KALA)?
